AtaiBeckley (ATAI) Current Leases (2022 - 2023)

AtaiBeckley (ATAI) reported Current Leases of $292000.0 for Q3 2023, down 9.32% sequentially from $322000.0 in Q2 2023.

AtaiBeckley (ATAI) Current Leases (2022 - 2023) Analysis & Trends

AtaiBeckley (ATAI) has 2 years of Current Leases data on file, last reported at $292000.0 in Q3 2023.

For the quarter ending Q3 2023, Current Leases changed N/A year-over-year to $292000.0; the trailing twelve-month figure through Sep 2023 stood at $292000.0 (changed N/A YoY), and the FY2022 full-year result was $180000.0, changed N/A from the prior year.
Current Leases fell to $292000.0 in Q3 2023, from $322000.0 in the prior quarter.
In the past five years, Current Leases ranged from a high of $322000.0 in Q2 2023 to a low of $180000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	531,233.95
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	20.58 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	872,589.03
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	720.00 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	11.00 Mn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	16.61 Mn
10	AtaiBeckley	2.56 Bn	2.56 Bn	-	-

Download Data